Phase 4
N=13
Effect of Valproic Acid Concentration on Photic Response
Photosensitive Epilepsy
Bottom Line
View on ClinicalTrials.gov: NCT00609245 ↗Enrolled (actual)
13
Serious AEs
3.9%
Results posted
Jun 2017
Primary outcome: Primary: Difference in SPR During Placebo and VPA Infusions — 15.917; 14.609 standard photosensitive range (SPR) — p=0.016
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Valproic Acid (Drug); Placebo (Drug)
- Age
- Pediatric, Adult, Older Adult · 15+ yrs
- Sex
- All
- Sponsor
- Vanderbilt University Medical Center
- Primary completion
- Dec 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Difference in SPR During Placebo and VPA Infusions |
15.917; 14.609 | 0.016 sig |
Summary
We are trying to learn if small changes in the amount of a valproate in the blood (given through an IV) will change the way the brain reacts to flashing lights.
Eligibility Criteria
Inclusion Criteria
- Male or female patients
- Aged 15 to 65 years
- Patients with a diagnosis of epilepsy for which they are either taking up two AEDs, not including VPA/divalproex, or no AEDs
- Patients with a reproducible IPS-induced photo-paroxysmal responses of at least 7 SPR-EEG units as measured at two different time points in the day (pm screening Study Visit 1 and am of Visit 2).
- Are in good health (with the exception of epilepsy).
- Able and willing to provide written informed consent.
Exclusion Criteria
- Patients not exhibiting a photo-paroxysmal-EEG response
- Patients with active psychogenic seizures
- Women who are pregnant or lactating
- Women of reproductive potential who do not agree to use effective birth-control methods during the study and for one week after receiving study drug.
- Patients taking any dosage form of VPA/divalproex within 4 weeks prior to the study
- Patients taking more than two concomitant AEDs
- Patients with any clinically significant laboratory abnormality, which in the opinion of the investigator, will exclude the patient from the study
- Patients who are suffering from active liver disease indicated by abnormal liver function tests greater than three times the upper limit of normal (AST and ALT), patients with porphyria, or patients with a family history of severe hepatic dysfunction
- Patients with a history of alcoholism, drug abuse, or drug addiction (within the past 12 months)
- Patients with a history of sensitivity or allergic reaction to valproate / divalproex
- Patients who have a medical history which would contraindicate sodium valproate (VPA) administration
- Patients who have participated in any other trials involving an investigational product or device within 30 days of screening.
- Patients with clinically significant ECG abnormalities, as judged by the PI, at screening visit
- Patients with such poor intravenous access that the insertion of two intravenous catheters (one for sodium valproate infusion and one, in a contralateral arm vein, for serial blood sampling) for a 12-hour period is not possible.
- Patients who received benzodiazepines within one week of study initiation
- Status epilepticus within one year of screening
- Generalized tonic-clonic seizure within 24 hours of photic stimulation procedure
Data sourced from ClinicalTrials.gov (NCT00609245). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.